Takuya Hayashi

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 6

Top Topics

Atrial Fibrillation

Top Venues

Journal of the American Heart Association

This page only lists publications with an associated author ORCID identifier.

Publications

Masaharu Akao, Takeshi Yamashita, Masayuki Fukuzawa, Takuya Hayashi, Ken Okumura
Efficacy and Safety of Low-Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE-AF Trial. Journal of the American Heart Association 13 (3) (2024)
Masaharu Akao, Takeshi Yamashita, Masayuki Fukuzawa, Takuya Hayashi, Ken Okumura
Efficacy and Safety of Low-Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE-AF Trial. Journal of the American Heart Association (2024)
Masaharu Akao, Takeshi Yamashita, Masayuki Fukuzawa, Takuya Hayashi, Ken Okumura
Efficacy and Safety of Low-Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE-AF Trial. Journal of the American Heart Association 13 (3) (2024)
Masaharu Akao, Takeshi Yamashita, Masayuki Fukuzawa, Takuya Hayashi, Ken Okumura
Efficacy and Safety of Low-Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE-AF Trial. Journal of the American Heart Association 13 (3) (2024)
Masaharu Akao, Takeshi Yamashita, Masayuki Fukuzawa, Takuya Hayashi, Ken Okumura
Efficacy and Safety of Low-Dose Edoxaban by Body Weight in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the Randomized ELDERCARE-AF Trial. Journal of the American Heart Association 13 (3) (2024)
Takeshi Mikami, Kagami Hirabayashi, Keisuke Okawa, Tetsuo Betsuyaku, Saori Watanabe, Yuki Imamura, Kimihiko Tanizawa, Takuya Hayashi, Masaharu Akao, Takeshi Yamashita, Ken Okumura
Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub-Analysis of the ELDERCARE-AF Trial. Journal of the American Heart Association 11 (17) (2022)